Effectiveness of chromium in atypical depression: A placebo-controlled trial
Effectiveness of chromium in atypical depression: A placebo-controlled trial
复制标题
DOI：
10.1016/s0006-3223(02)01500-7
复制
发表时间：
2003-02-01
影响因子：
10.6
通讯作者：
McLeod, MN
中科院分区：
文献类型：
--
作者：
Davidson, JRT;Abraham, K;McLeod, MN
背景：据报道，吡啶甲酸铬 (CP) 对有非典型抑郁症症状的患者有益。方法：对 15 名 DSM-IV 重度抑郁症（非典型型）患者进行了一项安慰剂对照、双盲、初步研究。患者接受 600 杯 CP 或匹配的安慰剂 (PBO)，持续 8 周。结果：七名 (70%) CP 和零名 (0%) PBO 患者符合反应者标准 (p = .02)。其他结果与 CP 的更大效果一致。三名接受 CP 治疗的患者没有表现出任何改善。吡啶甲酸铬的耐受性良好。结论：吡啶甲酸铬在非典型抑郁症中显示出良好的抗抑郁作用。其作用机制可能与 5HT(2A) 下调、胰岛素敏感性增加或其他作用有关。 (C) 2003 年生物精神病学协会。
Background: Chromium picolinate (CP) has been reported to benefit patients with symptoms of atypical depression.Methods: A placebo-controlled, double-blind, pilot study of CP was conducted in 15 patients with DSM-IV major depressive disorder, atypical type. Patients received 600 mug of CP or matching placebo (PBO) for 8 weeks.Results: Seven (70%) CP and zero (0%) PBO patients met responder criteria (p = .02). Other outcomes were consistent with greater effect of CP. Three patients on CP failed to show any improvement. Chromium picolinate was well tolerated.Conclusions: Chromium picolinate shows promising antidepressant effects in atypical depression. Its mechanism of action may relate to 5HT(2A) downregulation, increased insulin sensitivity, or to other effects. (C) 2003 Society of Biological Psychiatry.